Charles F Gilks

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6679805/publications.pdf Version: 2024-02-01

		34076	24961
228	13,445	52	109
papers	citations	h-index	g-index
231	231	231	10949
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet, The, 2009, 373, 48-57.	6.3	1,720
2	Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. Lancet Infectious Diseases, The, 2008, 8, 516-523.	4.6	681
3	The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings. Lancet, The, 2006, 368, 505-510.	6.3	580
4	23–valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: double-blind, randomised and placebo controlled trial. Lancet, The, 2000, 355, 2106-2111.	6.3	450
5	Cryptococcal infection in a cohort of HIV-1-infected Ugandan adults. Aids, 2002, 16, 1031-1038.	1.0	353
6	A Trial of a 7-Valent Pneumococcal Conjugate Vaccine in HIV-Infected Adults. New England Journal of Medicine, 2010, 362, 812-822.	13.9	321
7	Life-threatening bacteraemia in HIV-1 seropositive adults admitted to hospital in Nairobi, Kenya. Lancet, The, 1990, 336, 545-549.	6.3	290
8	Highly active antiretroviral treatment for the prevention of HIV transmission. Journal of the International AIDS Society, 2010, 13, 1-1.	1.2	285
9	Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial. Lancet, The, 2010, 375, 123-131.	6.3	267
10	Non-typhoidal salmonella bacteraemia among HIV-infected Malawian adults: high mortality and frequent recrudescence. Aids, 2002, 16, 1633-1641.	1.0	238
11	Effect of Human Immunodeficiency Virus (HIV) Type 1 Envelope Subtypes A and D on Disease Progression in a Large Cohort of HIVâ€1–Positive Persons in Uganda. Journal of Infectious Diseases, 2002, 185, 1244-1250.	1.9	227
12	Recommendations for surveillance of transmitted HIV drug resistance in countries scaling up antiretroviral treatment. Antiviral Therapy, 2008, 13, 25-36.	0.6	222
13	Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis. Lancet Infectious Diseases, The, 2009, 9, 409-417.	4.6	216
14	Prevention of mother-to-child transmission of HIV and the health-related Millennium Development Goals: time for a public health approach. Lancet, The, 2011, 378, 282-284.	6.3	212
15	Increasing rates of malarial fever with deteriorating immune status in HIV-1-infected Ugandan adults. Aids, 2001, 15, 899-906.	1.0	203
16	Isolation of Mycobacterium avium complex from water in the United States, Finland, Zaire, and Kenya. Journal of Clinical Microbiology, 1993, 31, 3227-3230.	1.8	196
17	Invasive pneumococcal disease in a cohort of predominantly HIV-1 infected female sex-workers in Nairobi, Kenya. Lancet, The, 1996, 347, 718-723.	6.3	195
18	The World Health Organization's global strategy for prevention and assessment of HIV drug resistance. Antiviral Therapy, 2008, 13, 1-13.	0.6	191

#	Article	IF	CITATIONS
19	Cutaneous hypersensitivity reactions due to thiacetazone in HIV-1 seropositive patients treated for tuberculosis. Lancet, The, 1991, 337, 627-630.	6.3	190
20	HIV infection as a cofactor for severe falciparum malaria in adults living in a region of unstable malaria transmission in South Africa. Aids, 2004, 18, 547-554.	1.0	173
21	Outcomes from monitoring of patients on antiretroviral therapy in resource-limited settings with viral load, CD4 cell count, or clinical observation alone: a computer simulation model. Lancet, The, 2008, 371, 1443-1451.	6.3	158
22	The Global Fight Against HIV/AIDS, Tuberculosis, and Malaria. American Journal of Clinical Pathology, 2009, 131, 844-848.	0.4	158
23	A Meta-analysis on the Role of Children in Severe Acute Respiratory Syndrome Coronavirus 2 in Household Transmission Clusters. Clinical Infectious Diseases, 2021, 72, e1146-e1153.	2.9	137
24	Severe Renal Dysfunction and Risk Factors Associated with Renal Impairment in HIVâ€Infected Adults in Africa Initiating Antiretroviral Therapy. Clinical Infectious Diseases, 2008, 46, 1271-1281.	2.9	134
25	Increased recurrence of tuberculosis in HIV-1-infected patients in Kenya. Lancet, The, 1993, 342, 332-337.	6.3	130
26	Isoniazid preventive therapy for tuberculosis in HIV-1-infected adults. Aids, 1997, 11, 875-882.	1.0	130
27	Motherâ€ŧo hild Transmission of Human Herpesvirus–8 in South Africa. Journal of Infectious Diseases, 2004, 190, 1068-1075.	1.9	125
28	Relationships between sequestration, antigenic variation and chronic parasitism in Plasmodium chabaudi chabaudi– a rodent malaria model. Parasite Immunology, 1990, 12, 45-64.	0.7	118
29	Pregnancy and Infant Outcomes among HIV-Infected Women Taking Long-Term ART with and without Tenofovir in the DART Trial. PLoS Medicine, 2012, 9, e1001217.	3.9	116
30	Antiretroviral Therapy Uptake, Attrition, Adherence and Outcomes among HIV-Infected Female Sex Workers: A Systematic Review and Meta-Analysis. PLoS ONE, 2014, 9, e105645.	1.1	113
31	Daily co-trimoxazole prophylaxis in severely immunosuppressed HIV-infected adults in Africa started on combination antiretroviral therapy: an observational analysis of the DART cohort. Lancet, The, 2010, 375, 1278-1286.	6.3	111
32	Malaria Attributable to the HIV-1 Epidemic, Sub-Saharan Africa. Emerging Infectious Diseases, 2005, 11, 1410-1419.	2.0	110
33	Trends in Bloodstream Infections among Human Immunodeficiency Virus–Infected Adults Admitted to a Hospital in Nairobi, Kenya, during the Last Decade. Clinical Infectious Diseases, 2001, 33, 248-256.	2.9	98
34	The international epidemiology of disseminated Mycobacterium avium complex infection in AIDS. Aids, 1996, 10, 1025-1032.	1.0	96
35	Extrapulmonary and disseminated tuberculosis in HIV-1-seropositive patients presenting to the acute medical services in Nairobi. Aids, 1990, 4, 981-986.	1.0	94
36	World Health Organization surveys to monitor HIV drug resistance prevention and associated factors in sentinel antiretroviral treatment sites. Antiviral Therapy, 2008, 13, 15-23.	0.6	89

#	Article	IF	CITATIONS
37	Chronic diarrhoea among HIV-infected adult patients in Nairobi, Kenya. Journal of Infection, 1998, 37, 48-53.	1.7	86
38	Evidence of Previous Infection with Mycobacterium avium-Mycobacterium intracellulare Complex among Healthy Subjects: An International Study of Dominant Mycobacterial Skin Test Reactions. Journal of Infectious Diseases, 1993, 168, 1553-1558.	1.9	80
39	Implementation of co-trimoxazole prophylaxis and isoniazid preventive therapy for people living with HIV. Bulletin of the World Health Organization, 2010, 88, 253-259.	1.5	80
40	Diarrhoea, CD4 Counts and Enteric Infections in a Community-Based Cohort of HIV-Infected Adults in Uganda. Journal of Infection, 2002, 45, 99-106.	1.7	79
41	Childhood malaria in a region of unstable transmission and high human immunodeficiency virus prevalence. Pediatric Infectious Disease Journal, 2003, 22, 1057-1063.	1.1	79
42	Initial outcomes of integrated community-based hepatitis C treatment for people who inject drugs: Findings from the Queensland Injectors' Health Network. International Journal of Drug Policy, 2017, 47, 216-220.	1.6	78
43	Fixed duration interruptions are inferior to continuous treatment in African adults starting therapy with CD4 cell counts &It 200 cells/μI. Aids, 2008, 22, 237-247.	1.0	74
44	Pneumococcal disease in HIV-infected Malawian adults: acute mortality and long-term survival. Aids, 2002, 16, 1409-1417.	1.0	73
45	Assessing the cost and willingness to pay for voluntary HIV counselling and testing in Kenya. Health Policy and Planning, 2002, 17, 187-195.	1.0	69
46	Mortality in the Year Following Antiretroviral Therapy Initiation in HIV-Infected Adults and Children in Uganda and Zimbabwe. Clinical Infectious Diseases, 2012, 55, 1707-1718.	2.9	68
47	Effectiveness of cotrimoxazole prophylaxis on mortality in adults with tuberculosis in rural South Africa. Aids, 2005, 19, 163-168.	1.0	67
48	Prevalence, Incidence and Predictors of Severe Anaemia with Zidovudine-Containing Regimens in African Adults with HIV Infection within the Dart Trial. Antiviral Therapy, 2006, 11, 741-750.	0.6	65
49	The clinical challenge of the HIV epidemic in the developing world. Lancet, The, 1993, 342, 1037-1039.	6.3	60
50	International recommendations on antiretroviral drugs for treatment of HIV-infected women and prevention of mother-to-child HIV transmission in resource-limited settings: 2006 update. American Journal of Obstetrics and Gynecology, 2007, 197, S42-S55.	0.7	59
51	Can antiretroviral therapy eliminate HIV transmission?. Lancet, The, 2009, 373, 7-9.	6.3	59
52	Biochemical mis-identification of Brucella melitensis and subsequent laboratory-acquired infections. Journal of Hospital Infection, 1992, 22, 159-162.	1.4	58
53	Disseminated Mycobacterium avium Infection Among HIV-Infected Patients in Kenya. Journal of Acquired Immune Deficiency Syndromes, 1995, 8, 195???198.	0.3	54
54	23-Valent pneumococcal polysaccharide vaccine in HIV-infected Ugandan adults. Aids, 2004, 18, 1210-1213.	1.0	54

#	Article	IF	CITATIONS
55	National adult antiretroviral therapy guidelines in resource-limited countries: concordance with 2003 WHO guidelines?. Aids, 2006, 20, 1497-1502.	1.0	52
56	Geographic Diversity of Human Immunodeficiency Virus Type 1: Serologic Reactivity to env Epitopes and Relationship to Neutralization. Journal of Infectious Diseases, 1992, 165, 256-261.	1.9	51
57	Ending the epidemic of HIV/AIDS by 2030: Will there be an endgame to HIV, or an endemic HIV requiring an integrated health systems response in many countries?. International Journal of Infectious Diseases, 2020, 100, 273-277.	1.5	51
58	Inverse association between BCG immunisation and intestinal nematode infestation among HIV-1-positive individuals in Uganda. Lancet, The, 1999, 354, 1000-1001.	6.3	49
59	Conjugate Pneumococcal Vaccine in HIVâ€Infected Ugandans and the Effect of Past Receipt of Polysaccharide Vaccine. Journal of Infectious Diseases, 2005, 192, 1801-1805.	1.9	49
60	Patterns of Individual and Population-Level Adherence to Antiretroviral Therapy and Risk Factors for Poor Adherence in the First Year of the DART Trial in Uganda and Zimbabwe. Journal of Acquired Immune Deficiency Syndromes (1999), 2008, 48, 468-475.	0.9	49
61	Genotypic Analysis of Multidrug-Resistant Salmonella enterica Serovar Typhi, Kenya. Emerging Infectious Diseases, 2000, 6, 649-651.	2.0	48
62	Pneumococcal vaccination in HIV-1-infected adults in Uganda. Aids, 1998, 12, 1683-1689.	1.0	47
63	Susceptibility of healthcare workers in Kenya to hepatitis B: new strategies for facilitating vaccination uptake. Journal of Hospital Infection, 2006, 64, 271-277.	1.4	47
64	Antiretroviral drugs as a public health intervention for pregnant HIV-infected women in rural South Africa. Aids, 1998, 12, 1675-1682.	1.0	46
65	Admission Trends in a Rural South African Hospital During the Early Years of the HIV Epidemic. JAMA - Journal of the American Medical Association, 1999, 282, 1087.	3.8	46
66	Viral Rebound and Emergence of Drug Resistance in the Absence of Viral Load Testing: A Randomized Comparison between Zidovudine‣amivudine plus Nevirapine and Zidovudine‣amivudine plus Abacavir. Journal of Infectious Diseases, 2010, 201, 106-113.	1.9	46
67	The operation, quality and costs of a district hospital laboratory service in Malawi. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2003, 97, 403-408.	0.7	45
68	Multi-drug resistant non-typhi salmonellae in Kenya. Journal of Antimicrobial Chemotherapy, 1996, 38, 425-434.	1.3	44
69	Responsiveness of Human Immunodeficiency Virus Type 1â€Infected Kenyan Women with or without Prior Pneumococcal Disease to Pneumococcal Vaccine. Journal of Infectious Diseases, 1997, 175, 975-978.	1.9	43
70	World Health Organization/HIVResNet Drug Resistance Laboratory Strategy. Antiviral Therapy, 2008, 13, 49-57.	0.6	43
71	Immune response following oral administration of cholera toxin B subunit to HIV-1-infected UK and Kenyan subjects. Aids, 1994, 8, 779-786.	1.0	39
72	Streptococcus pneumoniae resistant to penicillin and tetracycline associated with HIV seropositivity. Lancet, The, 1995, 346, 1034-1035.	6.3	38

#	Article	IF	CITATIONS
73	Working with risk: Occupational safety issues among healthcare workers in Kenya. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2008, 20, 304-310.	0.6	38
74	Analysis of the COVID-19 pandemic: lessons towards a more effective response to public health emergencies. Globalization and Health, 2022, 18, 10.	2.4	38
75	Recurrence of HIV-related tuberculosis in an endemic area may be due to relapse or reinfection. Tubercle and Lung Disease, 1994, 75, 199-202.	2.1	37
76	Recent transmission of tuberculosis in a cohort of HIV-1-infected female sex workers in Nairobi, Kenya. Aids, 1997, 11, 911-918.	1.0	37
77	Primary health care contributions to universal health coverage, Ethiopia. Bulletin of the World Health Organization, 2020, 98, 894-905A.	1.5	37
78	Acute bacterial infections and HIV disease. British Medical Bulletin, 1998, 54, 383-393.	2.7	36
79	High Rate of HIV Resuppression After Viral Failure on First-line Antiretroviral Therapy in the Absence of Switch to Second-line Therapy. Clinical Infectious Diseases, 2014, 58, 1023-1026.	2.9	36
80	Behaviour change in clients of health centre-based voluntary HIV counselling and testing services in Kenya. Sexually Transmitted Infections, 2007, 83, 541-546.	0.8	34
81	Clomerular Dysfunction and Associated Risk Factors over 4–5 Years following Antiretroviral Therapy Initiation in Africa. Antiviral Therapy, 2011, 16, 1011-1020.	0.6	34
82	Performance of the Antiretroviral Treatment Program in Ethiopia, 2005-2015: strengths and weaknesses toward ending AIDS. International Journal of Infectious Diseases, 2017, 60, 70-76.	1.5	34
83	Evaluation of microscope condition in Malawi. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2000, 94, 583-584.	0.7	33
84	A Caseâ€Control Study to Investigate Serological Correlates of Clinical Failure of 23â€Valent Pneumococcal Polysaccharide Vaccine in HIVâ€l–Infected Ugandan Adults. Journal of Infectious Diseases, 2004, 190, 707-712.	1.9	33
85	Scaling Up Treatment — Why We Can't Wait. New England Journal of Medicine, 2005, 353, 2392-2394.	13.9	32
86	Estimating Glomerular Filtration Rate in HIV-Infected Adults in Africa: Comparison of Cockcroft–Gault and Modification of Diet in Renal Disease Formulae. Antiviral Therapy, 2008, 13, 761-770.	0.6	32
87	Skin reactions to bug bites as a result of xenodiagnosis. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1981, 75, 405-408.	0.7	31
88	Fresh from the field: some controversies in tropical medicine and hygiene. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2000, 94, 233-237.	0.7	31
89	Paediatric HIV infection in a rural South African district hospital. Journal of Tropical Pediatrics, 2000, 46, 107-110.	0.7	31
90	Analysis of Salmonella enterica serotype Typhimurium by phage typing, antimicrobial susceptibility and pulsed-field gel electrophoresis. Journal of Medical Microbiology, 1999, 48, 1037-1042.	0.7	30

#	Article	IF	CITATIONS
91	Protease inhibitor-containing antiretroviral treatment and tuberculosis: can rifabutin fill the breach? [Review article]. International Journal of Tuberculosis and Lung Disease, 2012, 16, 6-15.	0.6	30
92	Knowing your HIV/AIDS epidemic and tailoring an effective response: how did India do it?. Sexually Transmitted Infections, 2012, 88, 240-249.	0.8	30
93	Nasopharyngeal carriage ofStaphylococcus aureus and carriage of tetracycline-resistant strains associated with HIV-seropositivity. European Journal of Clinical Microbiology and Infectious Diseases, 1995, 14, 34-40.	1.3	29
94	HIV Prevalence Among Tuberculosis Patients in Sub-Saharan Africa: A Systematic Review and Meta-analysis. AIDS and Behavior, 2019, 23, 1561-1575.	1.4	29
95	The changing impact of HIV/AIDS on Kenyatta National Hospital, Nairobi from 1988/89 through 1992 to 1997. Aids, 2000, 14, 1625-1631.	1.0	28
96	Utility assessment of HIV/AIDS-related health states in HIV-infected Ugandans. Aids, 2008, 22, S123-S130.	1.0	28
97	Serotypes and antibiotic susceptibilities of Streptococcus pneumoniae in Nairobi, Kenya. Journal of Infection, 1996, 32, 139-142.	1.7	27
98	Some Effects of the Rising Case Load of Adult HIV-Related Disease on a Hospital in Nairobi. Journal of Acquired Immune Deficiency Syndromes, 1998, 18, 234-240.	0.3	27
99	Eosinophilia and progression to active tuberculosis in HIV-1-infected Ugandans. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2003, 97, 477-480.	0.7	27
100	A Polymorphism That Reduces RANTES Expression Is Associated with Protection from Death in HIV‧eropositive Ugandans with Advanced Disease. Journal of Infectious Diseases, 2006, 194, 666-669.	1.9	27
101	Twentyâ€fourâ€week safety and tolerability of nevirapine <i>vs.</i> abacavir in combination with zidovudine/lamivudine as firstâ€line antiretroviral therapy: a randomized doubleâ€blind trial (NORA) [*] . Tropical Medicine and International Health, 2008, 13, 6-16.	1.0	27
102	Rhodococcus equi and HIV-1 Infection in Uganda. Journal of Infection, 2000, 41, 227-231.	1.7	26
103	The role of HIV testing, counselling, and treatment in coping with HIV/AIDS in Uganda: a qualitative analysis. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2009, 21, 903-908.	0.6	26
104	The risks and benefits of childhood bacille Calmette-Guérin immunization among adults with AIDS. Aids, 1997, 11, 669-672.	1.0	25
105	Increasing frequency of tuberculosis among staff in a South African district hospital: impact of the HIV epidemic on the supply side of health care. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1998, 92, 500-502.	0.7	25
106	Cytokine responses and progression to active tuberculosis in HIV-1-infected Ugandans: a prospective study. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2004, 98, 660-670.	0.7	25
107	Cost Effectiveness Analysis of Clinically Driven versus Routine Laboratory Monitoring of Antiretroviral Therapy in Uganda and Zimbabwe. PLoS ONE, 2012, 7, e33672.	1.1	25
108	The Lablite project: A cross-sectional mapping survey of decentralized HIV service provision in Malawi, Uganda and Zimbabwe. BMC Health Services Research, 2014, 14, 352.	0.9	25

#	Article	IF	CITATIONS
109	The Role for Government Health Centers in Provision of Same-Day Voluntary HIV Counseling and Testing in Kenya. Journal of Acquired Immune Deficiency Syndromes (1999), 2005, 40, 329-335.	0.9	24
110	Nevirapine/zidovudine/lamivudine has superior immunological and virological responses not reflected in clinical outcomes in a 48â€week randomized comparison with abacavir/zidovudine/lamivudine in HIVâ€infected Ugandan adults with low CD4 cell counts. HIV Medicine, 2010, 11, 334-344.	1.0	24
111	Distribution of <i>HLAâ€B</i> alleles in a Ugandan HIVâ€infected adult population: NORA pharmacogenetic substudy of DART. Tropical Medicine and International Health, 2011, 16, 200-204.	1.0	24
112	Characterization of Streptococcus pneumoniae from Human Immunodeficiency Virus-Seropositive Patients with Acute and Recurrent Pneumonia. Journal of Infectious Diseases, 1995, 172, 983-987.	1.9	23
113	Molecular typing of multi-drug resistant Shigella dysenteriae type 1 by plasmid analysis and pulsed-field gel electrophoresis. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1996, 90, 712-714.	0.7	23
114	Failure of penicillin prophylaxis in laboratory acquired leptospirosis Postgraduate Medical Journal, 1988, 64, 236-238.	0.9	22
115	No association between meningococcal disease and human immunodeficiency virus in adults in Nairobi, Kenya. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1991, 85, 651.	0.7	22
116	Toxoplasma antibodies in HIV-positive patients from Nairobi. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1991, 85, 750-751.	0.7	22
117	Use of clinical judgement to guide administration of blood transfusions in Malawi. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2001, 95, 510-512.	0.7	22
118	A CD45 polymorphism associated with abnormal splicing is absent in African populations. Immunogenetics, 2002, 53, 980-983.	1.2	22
119	Chemokine-receptor genes and AIDS risk. Nature, 2002, 417, 140-140.	13.7	22
120	Serological responses to brucellosis in HIV-seropositive patients. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1995, 89, 228-230.	0.7	21
121	Costs of hospital care for HIV-positive and HIV-negative patients at Kenyatta National Hospital, Nairobi, Kenya. Aids, 2002, 16, 901-908.	1.0	21
122	The charms and challenges of antiretroviral therapy in Uganda: the DART experience. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2012, 24, 137-142.	0.6	21
123	Reimagining global health systems for the 21st century: lessons from the COVID-19 pandemic. BMJ Global Health, 2021, 6, e004882.	2.0	21
124	Cotrimoxazole prophylaxis in adults infected with HIV in low-income countries. Current Opinion in Infectious Diseases, 2001, 14, 507-512.	1.3	20
125	Evolution of Drug Resistance During 48 Weeks of Zidovudine/Lamivudine/Tenofovir in the Absence of Real-Time Viral Load Monitoring. Journal of Acquired Immune Deficiency Syndromes (1999), 2010, 55, 277-283.	0.9	20
126	Reducing the risk of nosocomial HIV infection in British health workers working overseas: role of post-exposure prophylaxis. BMJ: British Medical Journal, 1998, 316, 1158-1160.	2.4	20

#	Article	IF	CITATIONS
127	Bacteriuria in a cohort of predominantly HIV-1 seropositive female commercial sex workers in Nairobi, Kenya. Journal of Infection, 1996, 33, 33-37.	1.7	19
128	Universal voluntary HIV testing and immediate antiretroviral therapy – Authors' reply. Lancet, The, 2009, 373, 1080-1081.	6.3	19
129	Towards achieving the fast-track targets and ending the epidemic of HIV/AIDS in Ethiopia: Successes and challenges. International Journal of Infectious Diseases, 2019, 78, 57-64.	1.5	19
130	Carriage of Potentially Pathogenic Escherichia coli in Chickens. Avian Diseases, 2002, 46, 721-724.	0.4	18
131	Trends in Adult Medical Admissions in a Rural South African Hospital Between 1991 and 2002. Journal of Acquired Immune Deficiency Syndromes (1999), 2005, 40, 53-56.	0.9	17
132	A Single CD4 Test with 250 Cells/Mm3 Threshold Predicts Viral Suppression in HIV-Infected Adults Failing First-Line Therapy by Clinical Criteria. PLoS ONE, 2013, 8, e57580.	1.1	17
133	Implementation of Antiretroviral Therapy for Life in Pregnant/Breastfeeding HIV+ Women (Option B+) Alongside Rollout and Changing Guidelines for ART Initiation in Rural Zimbabwe: The Lablite Project Experience. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 74, 508-516.	0.9	17
134	Evidence for Reduced Drug Susceptibility without Emergence of Major Protease Mutations following Protease Inhibitor Monotherapy Failure in the SARA Trial. PLoS ONE, 2015, 10, e0137834.	1.1	17
135	AIDS, monkeys and malaria. Nature, 1991, 354, 262-262.	13.7	16
136	The Impact of Different CD4 Cell-Count Monitoring and Switching Strategies on Mortality in HIV-Infected African Adults on Antiretroviral Therapy: An Application of Dynamic Marginal Structural Models. American Journal of Epidemiology, 2015, 182, 633-643.	1.6	16
137	Reduced sensitivity from pooled urine, pharyngeal and rectal specimens when using a molecular assay for the detection of chlamydia and gonorrhoea near the point of care. Sexual Health, 2020, 17, 15.	0.4	16
138	Global health security and universal health coverage: Understanding convergences and divergences for a synergistic response. PLoS ONE, 2020, 15, e0244555.	1.1	16
139	Lopinavir/Ritonavir Monotherapy after 24 Weeks of Second-Line Antiretroviral Therapy in Africa: A Randomized Controlled Trial (Sara). Antiviral Therapy, 2012, 17, 1363-1373.	0.6	15
140	Gag-Protease Sequence Evolution Following Protease Inhibitor Monotherapy Treatment Failure in HIV-1 Viruses Circulating in East Africa. AIDS Research and Human Retroviruses, 2015, 31, 1032-1037.	0.5	15
141	Rapid accumulation of HIV-1 thymidine analogue mutations and phenotypic impact following prolonged viral failure on zidovudine-based first-line ART in sub-Saharan Africa. Journal of Antimicrobial Chemotherapy, 2017, 72, 1450-1455.	1.3	15
142	Exploring the population-level impact of antiretroviral treatment. Aids, 2014, 28, S61-S72.	1.0	14
143	Hepatitis B serological markers and plasma DNA concentrations. Aids, 2017, 31, 1109-1117.	1.0	14
144	Seroprevlance of Coxiella burnetii among abattoir and slaughterhouse workers: A meta-analysis. One Health, 2018, 6, 23-28.	1.5	14

#	Article	IF	CITATIONS
145	Economic issues and antiretroviral therapy in developing countries. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1999, 93, 1-3.	0.7	13
146	An Improved Algorithm for Determining HIV Type 1 Subtypes in a Primary Laboratory in Uganda. AIDS Research and Human Retroviruses, 2000, 16, 621-625.	0.5	13
147	Impact of second-line antiretroviral regimens on lipid profiles in an African setting: the DART trial sub-study. AIDS Research and Therapy, 2014, 11, 32.	0.7	13
148	Leaving no one behind: lessons from implementation of policies for universal HIV treatment to universal health coverage. Globalization and Health, 2020, 16, 17.	2.4	13
149	Host diet in experimental rodent malaria: a variable which can compromise experimental design and interpretation. Parasitology, 1989, 98, 175-177.	0.7	12
150	Pneumococcal Disease and HIV Infection. Annals of Internal Medicine, 1993, 118, 393.	2.0	12
151	The lost children of universal access – issues in scaling-up HIV testing and counselling. Vulnerable Children and Youth Studies, 2006, 1, 44-55.	0.5	12
152	Hepatitis C cascade of care at an integrated community facility for people who inject drugs. Journal of Substance Abuse Treatment, 2020, 114, 108025.	1.5	12
153	No increased prevalence of adrenocortical insufficiency in human immunodeficiency virus-associated tuberculosis. Tubercle and Lung Disease, 1996, 77, 444-448.	2.1	11
154	Clinical, epidemiological and preventative aspects. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1997, 91, 627-631.	0.7	11
155	Prevalence, incidence and predictors of peripheral neuropathy in African adults with HIV infection within the DART trial. Aids, 2014, 28, 2579-2588.	1.0	11
156	Population level usage of health services, and HIV testing and care, prior to decentralization of antiretroviral therapy in Agago District in rural Northern Uganda. BMC Health Services Research, 2015, 15, 527.	0.9	11
157	Implications of the on-line market for regulation and uptake of HIV self-testing in Australia. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2017, 29, 112-117.	0.6	11
158	Are intestinal helminths a risk factor for non-typhoidalSalmonellabacteraemia in adults in Africa who are seropositive for HIV? A case-control study. Annals of Tropical Medicine and Parasitology, 2002, 96, 203-208.	1.6	10
159	Tobacco Harm Reduction with Vaporised Nicotine (THRiVe): The Study Protocol of an Uncontrolled Feasibility Study of Novel Nicotine Replacement Products among People Living with HIV Who Smoke. International Journal of Environmental Research and Public Health, 2017, 14, 799.	1.2	10
160	Shifting human resources for health in the context of ART provision: qualitative and quantitative findings from the Lablite baseline study. BMC Health Services Research, 2016, 16, 660.	0.9	9
161	Vaporised nicotine and tobacco harm reduction for addressing smoking among people living with HIV: A cross-sectional survey of Australian HIV health practitioners' attitudes. Drug and Alcohol Dependence, 2017, 177, 67-70.	1.6	9
162	High Level of Viral Suppression and Low Switch Rate to Second-Line Antiretroviral Therapy among HIV-Infected Adult Patients Followed over Five Years: Retrospective Analysis of the DART Trial. PLoS ONE, 2014, 9, e90772.	1.1	9

#	Article	IF	CITATIONS
163	Online HIV Self-Testing (HIVST) Dissemination by an Australian Community Peer HIV Organisation: A Scalable Way to Increase Access to Testing, Particularly for Suboptimal Testers. International Journal of Environmental Research and Public Health, 2021, 18, 11252.	1.2	9
164	A Practical Approach to the Clinical Problems of the HIV-Infected Adult in the Tropics. Tropical Doctor, 1991, 21, 90-97.	0.2	8
165	HLA-A, -B, -C, -DRB1, DRB3, DRB4, DRB5 and DQB1 Polymorphism Detected by PCR-SSP in a Semi-Urban HIV-Positive Ugandan Population. Experimental and Clinical Immunogenetics, 1999, 16, 17-25.	1.4	8
166	HIV care in non-industrialised countries. British Medical Bulletin, 2001, 58, 171-186.	2.7	8
167	Second-line antiretroviral therapy: so much to be done. Lancet HIV,the, 2017, 4, e424-e425.	2.1	8
168	Impact of decentralisation of antiretroviral therapy services on HIV testing and care at a population level in Agago District in rural Northern Uganda: results from the Lablite population surveys. International Health, 2017, 9, 91-99.	0.8	8
169	Q fever vaccine efficacy and occupational exposure risk in Queensland, Australia: A retrospective cohort study. Vaccine, 2020, 38, 6578-6584.	1.7	8
170	Factors associated with pyomyositis: A systematic review and metaâ€analysis. Tropical Medicine and International Health, 2021, 26, 1210-1219.	1.0	8
171	The radiographic appearance of pneumococcal pneumonia in adults is unaltered by HIV-1-infection in hospitalized Kenyans. Aids, 2002, 16, 2095-2096.	1.0	8
172	Typhoid: an unusual cause of gastrointestinal bleeding. British Journal of Radiology, 1984, 57, 344-346.	1.0	7
173	Cutaneous hypersensitivity reactions to thiacetazone, HIV infection and thiacetazone concentrations in plasma. British Journal of Clinical Pharmacology, 1996, 41, 160-162.	1.1	7
174	Protein conjugate pneumococcal vaccines. BMJ: British Medical Journal, 2002, 324, 750-751.	2.4	7
175	Pharmacokinetics of Lopinavir-Ritonavir with and without Nonnucleoside Reverse Transcriptase Inhibitors in Ugandan HIV-Infected Adults. Antimicrobial Agents and Chemotherapy, 2010, 54, 2965-2973.	1.4	7
176	Australian interdisciplinary healthcare providers' perspectives on the effects of broader pre-exposure prophylaxis (PrEP) access on uptake and service delivery: a qualitative study. Sexual Health, 2020, 17, 485.	0.4	7
177	Comparative humoral responses to HIV-1 p24gag and gp120env in subjects from East Africa and the UK. Aids, 1991, 5, 1015-1020.	1.0	6
178	General Practitioner Antimicrobial Stewardship Programme Study (GAPS): protocol for a cluster randomised controlled trial. BMC Family Practice, 2016, 17, 48.	2.9	6
179	Patient-level benefits associated with decentralization of antiretroviral therapy services to primary health facilities in Malawi and Uganda. International Health, 2018, 10, 8-19.	0.8	6
180	Improved sensitivity from pooled urine, pharyngeal and rectal specimens when using a molecular assay for the detection of chlamydia and gonorrhoea near point of care. Sexually Transmitted Infections, 2021, 97, 471-472.	0.8	6

#	Article	IF	CITATIONS
181	STI and HIV knowledge and testing: a comparison of domestic Australian-born, domestic overseas-born and international university students in Australia. Sexual Health, 2021, 18, 346-348.	0.4	6
182	Peer-delivered point-of-care testing for Chlamydia trachomatis and Neisseria gonorrhoeae within an urban community setting: a cross-sectional analysis. Sexual Health, 2020, 17, 359.	0.4	6
183	Spontaneous and induced abortions at Kenyatta National Hospital, Nairobi, Kenya. International Journal of Gynecology and Obstetrics, 1993, 41, 182-183.	1.0	5
184	Polyuria in association with Plasmodium falciparum malaria in a region of unstable transmission. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2004, 98, 255-260.	0.7	5
185	Autopsies and better data on causes of death in Africa. Lancet Infectious Diseases, The, 2015, 15, 492-494.	4.6	5
186	Integrated HIV self-testing (HIVST) service delivery in Queensland for policy and service development: study protocol. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2019, 31, 207-215.	0.6	5
187	Tuberculosis in perspective. Lancet, The, 1992, 339, 748.	6.3	4
188	Impact of HIV in sub-Saharan Africa. Lancet, The, 1995, 346, 187.	6.3	4
189	Pneumocystis carinii pneumonia in Africa. Lancet, The, 1996, 347, 126-127.	6.3	4
190	Addressing smoking among people living with HIV: a cross-sectional survey of Australian HIV health practitioners' practices and attitudes. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2019, 31, 436-442.	0.6	4
191	Attributes of national governance for an effective response to public health emergencies: Lessons from the response to the COVID-19 pandemic. Journal of Global Health, 0, 12, .	1.2	4
192	Amodiaquine and malaria prophylaxis. Parasitology Today, 1986, 2, 209-211.	3.1	3
193	Tropical medicine in the HIV/AIDS era. Lancet, The, 1997, 349, S17-S18.	6.3	3
194	Changes in antiretroviral therapy guidelines: implications for public health policy and public purses. Sexually Transmitted Infections, 2010, 86, 388-390.	0.8	3
195	Phenotypic and genotypic analyses to guide selection of reverse transcriptase inhibitors in second-line HIV therapy following extended virological failure in Uganda. Journal of Antimicrobial Chemotherapy, 2014, 69, 1938-1944.	1.3	3
196	The virological durability of first-line ART among HIV-positive adult patients in resource limited settings without virological monitoring: a retrospective analysis of DART trial data. BMC Infectious Diseases, 2017, 17, 160.	1.3	3
197	Towards a universal second-line fixed-dose combination ART. Lancet HIV,the, 2018, 5, e3-e5.	2.1	3
198	A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults. Malawi Medical Journal, 2016, 28, 115-122.	0.2	3

#	Article	IF	CITATIONS
199	CLUSTERS OF SHINGLES. Lancet, The, 1985, 326, 1433-1434.	6.3	2
200	DOXYCYCLINE PROPHYLAXIS IN MALARIA. Lancet, The, 1987, 329, 1487.	6.3	2
201	Lessons to be learned from tuberculosis control in China. Lancet, The, 1996, 347, 835-836.	6.3	2
202	Improving HIV/AIDS disease surveillance in low-income countries. Aids, 1997, 11, 1881-1882.	1.0	2
203	Testing sputum samples for HIV antibodies, using a rapid, saliva-card test system. Annals of Tropical Medicine and Parasitology, 1997, 91, 115-117.	1.6	2
204	Monitoring of antiretroviral therapy in low-resource settings – Authors' reply. Lancet, The, 2008, 372, 289.	6.3	2
205	Cost-effectiveness of Strategies for Monitoring the Response to Antiretroviral Therapy in Resource-Limited Settings. Archives of Internal Medicine, 2009, 169, 904.	4.3	2
206	Lack of Minority K65R-Resistant Viral Populations Detected After Repeated Treatment Interruptions of Tenofovir/Zidovudine and Lamivudine in a Resource-Limited Setting. Journal of Acquired Immune Deficiency Syndromes (1999), 2010, 54, 215-216.	0.9	2
207	CD8+T-Cell Responses before and after Structured Treatment Interruption in Ugandan Adults Who Initiated ART with CD4+T Cells <200 Cell/μL: The DART Trial STI Substudy. AIDS Research and Treatment, 2011, 2011, 1-10.	0.3	2
208	Residual Activity of Two HIV Antiretroviral Regimens Prescribed without Virological Monitoring. Antimicrobial Agents and Chemotherapy, 2011, 55, 4575-4580.	1.4	2
209	Changes over time in creatinine clearance and comparison of emergent adverse events for HIV-positive adults receiving standard doses (300 mg/day) of lamivudine-containing antiretroviral therapy with baseline creatinine clearance of 30–49 vs ≥50 mL/min. PLoS ONE, 2019, 14, e0225199.	1.1	2
210	Reasons for Not Seeking Hepatitis C Treatment among People Who Inject Drugs. Substance Use and Misuse, 2021, 56, 175-184.	0.7	2
211	Economic evaluation of alternative testing regimes and settings to detect undiagnosed HIV in Australia. BMC Health Services Research, 2021, 21, 30.	0.9	2
212	Mixed malarial infection due to Plasmodium falciparum and P vivax BMJ: British Medical Journal, 1985, 291, 603-604.	2.4	2
213	Human T-cell leukaemia virus type 1 and Adult T-cell leukaemia/lymphoma in Queensland, Australia: a retrospective cross-sectional study. Sexually Transmitted Infections, 2023, 99, 50-52.	0.8	2
214	CYCADS AND SAGO. Lancet, The, 1988, 331, 181-182.	6.3	1
215	Man, monkeys and malaria. Philosophical Transactions of the Royal Society B: Biological Sciences, 2001, 356, 921-922.	1.8	1
216	New Insights on Long-Term Hepatitis B Virus Responses in HIV–Hepatitis B virus Co-infected Patients: Implications for Antiretroviral Management in Hepatitis B virus-Endemic Settings. Journal of Acquired Immune Deficiency Syndromes (1999), 2021, 86, 98-103.	0.9	1

#	Article	IF	CITATIONS
217	Points: More than just "no tobacco": Oxfam's Stewardship Fund. BMJ: British Medical Journal, 1985, 291, 827-827.	2.4	Ο
218	The Nuclear Arms Race and the Third World. JAMA - Journal of the American Medical Association, 1985, 254, 608.	3.8	0
219	Pneumococcal Disease in Sub-Saharan Africa: Could Currently Available Vaccines Avert a Crisis?. Tropical Doctor, 1999, 29, 5-7.	0.2	0
220	DART and laboratory monitoring of HIV treatment – Authors' reply. Lancet, The, 2010, 375, 979-980.	6.3	0
221	HIV disease in Africa. Revista Da Sociedade Brasileira De Medicina Tropical, 1993, 26, 135-139.	0.4	0
222	Acute Bacterial Infections. , 1997, , 235-250.		0
223	Title is missing!. , 2020, 15, e0244555.		0
224	Title is missing!. , 2020, 15, e0244555.		0
225	Title is missing!. , 2020, 15, e0244555.		0
226	Title is missing!. , 2020, 15, e0244555.		0
227	Title is missing!. , 2020, 15, e0244555.		0
228	Title is missing!. , 2020, 15, e0244555.		0